The changing face of PR and why it matters to regenmed
This may seem a little off-topic for those who don't know me but for those of you who do, you'll know this is a little mix of many of my primary loves - cell therapy/regenerative medicine, Continue Reading
Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10
Stewart Lyman of Lyman BioPharma Consulting posted a great article in today's Xconomy summarizing some key points and links to more information about the rules governing the Therapeutic Discovery Continue Reading
Google to Invest in Regenerative Medicine
While the US government prints money to shore up failing and broken business models which no one likes but are considered simply too big (not too important or significant or even useful) to fail, Continue Reading
Latest Cell Therapy Approval by FDA. Dendreon’s Provenge.
It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of Continue Reading
Stem cells for a Webby!
I know I haven't been a very good blogger for quite some time but I wanted to pass on a letter I just received from my friend James Price as a Charter member of the Canadian Stem Cell Foundation. Continue Reading
